Cardiac
-
CMS proposes Medicare coverage expansion for TAVR
The proposed Medicare coverage change could help Edwards Lifesciences gain market share from Medtronic and Boston Scientific, an analyst said.
By Susan Kelly • June 16, 2026 -
J&J recalls Impella controllers over hardware issues
The correction is the latest recall that J&J’s Abiomed has issued in recent years for Impella devices and controllers.
By Nick Paul Taylor • June 12, 2026 -
Explore the Trendline➔
Permission granted by Boston Scientific
TrendlineNew medical devices are reshaping the medtech industry
From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.
By MedTech Dive staff -
Edwards gets FDA approval for surgical tricuspid valve
Built specifically to mimic the native tricuspid anatomy, the implant is intended to address an unmet patient need.
By Susan Kelly • June 3, 2026 -
J&J recalls Impella heart pumps after patient dies
Johnson & Johnson asked customers to quarantine and return affected products. A spokesperson said J&J conducted quality system audits as part of its integration of Abiomed that resulted in some field actions.
By Nick Paul Taylor • May 29, 2026 -
J&J corrects Impella controller over issue linked to 2 injuries, 1 death
The controller can stop for about 35 seconds, during which time the patient is unsupported by the heart pump.
By Nick Paul Taylor • May 26, 2026 -
Retrieved from Medtronic on May 11, 2026
Medtronic to create European software hub in Ireland
The investment in cardiac digital health will add 85 jobs initially, with more growth expected over the next three years.
By Susan Kelly • May 22, 2026 -
Medtronic data back renal denervation in the long term
Analyses presented at EuroPCR assessed Medtronic’s Symplicity blood pressure procedure in patient groups with severe hypertension and who had prior cardiovascular events.
By Susan Kelly • May 20, 2026 -
Endologix buys clot removal system from Surmodics
Endologix will market the system to vascular interventionists who use its other devices to treat peripheral artery disease and abdominal aortic aneurysms.
By Nick Paul Taylor • May 20, 2026 -
Boston Scientific posts positive data for coronary IVL catheter
With the study results, Boston Scientific plans a regulatory submission for the intravascular lithotripsy treatment for patients with severely calcified coronary artery disease.
By Susan Kelly • May 19, 2026 -
Artivion closes Endospan buyout to acquire recently approved heart device
Artivion is targeting a $150 million annual U.S. market for the Nexus Aortic Arch System.
By Nick Paul Taylor • May 19, 2026 -
Boston Scientific buys $1.5B stake in TAVR developer MiRus
The deal gives Boston Scientific a 34% equity stake in MiRus and an option to acquire its TAVR platform by making additional payments totaling $3 billion.
By Susan Kelly • May 18, 2026 -
J&J launches improved Shockwave catheter
The latest generation of the coronary intravascular lithotripsy device is designed to be more flexible to help physicians navigate tight arteries to break up calcified deposits and restore blood flow.
By Susan Kelly • May 13, 2026 -
Retrieved from Medtronic on May 11, 2026
Medtronic to close California site amid restructuring
The decision to wind down the operation in Santa Rosa in about two years comes as the medtech giant combines several businesses within its cardiovascular portfolio.
By Susan Kelly • May 11, 2026 -
Abbott gets FDA nod, CE mark for AI-enabled imaging device
The device joins a portfolio of vascular technologies that generated 9.5% sales growth on a comparable basis in the first quarter.
By Nick Paul Taylor • May 4, 2026 -
Medtronic wins FDA approval for updated mitral replacement valve
Surgeons have performed initial implants of the Mosaic Neo valve at centers across the U.S., as well as the first robotic implantation.
By Susan Kelly • April 29, 2026 -
J&J starts head-to-head PFA trial against Boston Scientific device
The study will compare outcomes on J&J’s Varipulse Pro platform and Boston Scientific’s rival Farapulse PFA system.
By Nick Paul Taylor • April 28, 2026 -
4 studies to know from HRS 2026
Boston Scientific, Abbott and Medtronic shared new cardiac device data at the annual Heart Rhythm Society meeting, where market share shifts in pulsed field ablation were on analysts’ minds.
By Susan Kelly • April 27, 2026 -
J&J to acquire Atraverse Medical
The FDA-cleared radiofrequency guidewire will slot into J&J’s fast-growing cardiovascular portfolio.
By Nick Paul Taylor • April 27, 2026 -
Edwards raises 2026 forecast as TAVR sales surge
The stronger outlook follows mixed results from other major medical device makers in the latest quarter, after both Abbott and Boston Scientific cut their full-year guidance.
By Susan Kelly • April 24, 2026 -
Medtronic leads $100M investment in Pulnovo Medical
Medtronic formed a commercial agreement with Pulnovo alongside its investment.
By Nick Paul Taylor • April 21, 2026 -
Medtronic closes $585M purchase of CathWorks
The deal is the second tuck-in acquisition this year for Medtronic, which has signaled its intent to pursue more M&A in its core business lines.
By Susan Kelly • April 20, 2026 -
Stryker to buy Amplitude Vascular Systems
Amplitude’s intravascular lithotripsy technology could emerge as a challenger to Shockwave IVL, Leerink Partners analyst Mike Kratky wrote.
By Elise Reuter • April 13, 2026 -
Pulse Biosciences hires Liane Teplitsky as COO
The appointment gives a former Abbott leader oversight of efforts to bring a pulsed field ablation device to market.
By Nick Paul Taylor • April 10, 2026 -
J&J launches enhanced PFA device in Europe
The Varipulse Pro pulsed field ablation platform, which has received a CE mark, will be a focus at the upcoming European Heart Rhythm Association annual meeting in Paris.
By Susan Kelly • April 7, 2026 -
J&J’s Impella heart pump shows no patient benefit in 2 trials
Study investigators cautioned against routine use of the device in complex percutaneous coronary interventions and to treat heart attack patients who don’t have cardiogenic shock.
By Susan Kelly • April 1, 2026